COMPANY PROFILE

Leto Laboratories

Explore full profile

A manufacturer of protein products

Dongcheng District, ChinaFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Leto Laboratories

Leto Laboratories specializes in cutting-edge protein technologies and drug development, focusing on oncology, peptide, and cytokine therapies. The company operates in the biotechnology and pharmaceutical markets, serving clients ranging from research institutions to pharmaceutical companies. Leto Laboratories leverages proprietary technology platforms such as LetoFOLD for protein refolding, along with advanced screening, purification, and engineering design techniques. Its business model revolves around developing first-in-class drugs and high-potential early-stage discoveries, generating revenue through partnerships, licensing agreements, and direct sales of its proprietary technologies and products. The company's team comprises experienced professionals with expertise in both local and international markets, ensuring a robust pipeline of innovative solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Dongcheng District, China
Employees: 6
Open positions: None listed
Dealroom signal: 57.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	Jul 2025	—	—	Hankang Capital	↗
GROWTH EQUITY VCEquity / VC	Jan 2024	$0	—	Yun Hao Capital	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Leto Laboratories website traffic

Latest recorded traffic for Leto Laboratories is 30 monthly website visits, down 92.5% over the last three months. Leto Laboratories's team grew 0% over the past year.

Latest monthly visits30 3-month web change-92.5% 1-year team growth0%

Monthly website visitsOct 2020–Aug 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational	19	$60M	$240M
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
PBProtai BioIlluminating the druggable Proteome for better cures	Tel Aviv-Yafo, Israel	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed
RPRecludix PharmaDeveloping platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries	Cambridge, United States	Operational
WTWalking Fish TherapeuticsRapidly advancing cell-based therapeutics to treat serious diseases, concentrating on oncology and regenerative therapies	South San Francisco, United States	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational